Clinical Trials Browser

Interventional × cobimetinib × Clear all

NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05691504 2026-04-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Phase 1 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

NCT04302025 2026-04-03

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT04835805 2026-03-30

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase 1 Active not recruiting

Melanoma

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07449754 2026-03-04

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Phase 2 Recruiting

Melanoma

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04409639 2026-02-12

CONCERTO

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT04109456 2026-01-15

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase 2 Active not recruiting

Inflammatory Breast Neoplasms

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05034627 2025-11-28

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 4 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03600701 2025-10-07

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04079179 2025-09-18

NACHO-COBI

Phase 2 Recruiting

Histiocytosis, Langerhans-Cell, Xanthogranuloma, Juvenile, Histiocytosis, Sinus, Histiocytic Disorders, Malignant, Erdheim-Chester Disease, Histiocytic Sarcoma

NCT05441514 2025-09-16

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 3 FDA

Melanoma

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT04941287 2025-05-23

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Phase 2 Active not recruiting

57 enrolled 13 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02902029 2025-04-09

ImmunoCobiVem

Phase 2 Completed

Melanoma

NCT04722575 2025-03-13

NEO-TIM

Phase 2 Active not recruiting

Melanoma

NCT03224767 2025-02-18

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Phase 2 Active not recruiting

Craniopharyngioma

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

Multiple Myeloma

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

1,163 enrolled 33 charts 2 FDA

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04214418 2024-12-18

MEKiAUTO

Phase 1/2 Terminated

27 enrolled 12 charts

Gastrointestinal

Gastrointestinal Neoplasms

NCT04185831 2024-08-22

MEGALiT

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

5 enrolled 10 charts

Melanoma

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04216953 2024-07-08

COTESARC

Phase 1/2 Active not recruiting

Sarcoma

NCT03395899 2024-06-18

ECLIPSE

Phase 2 Completed

Breast Neoplasms

NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Phase 1 Terminated

CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02291289 2024-05-06

MODUL

Phase 2 Completed

1,044 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT03625141 2024-04-11

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Phase 2 Completed

80 enrolled 20 charts

Melanoma